Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Passes SBIR Reauthorization, Loosens VC Restrictions

This article was originally published in The Pink Sheet Daily

Executive Summary

No single investor owns 50 percent or more of a firm and no single VC company controls a firm’s board, under House bill.

You may also be interested in...



Revamp Of Small Business Funding Scheme Set For Yet Another Delay By Congress

SBIR update: House and Senate can't agree in time on bill prized by cash-hungry biotech industry. End-of-January deadline is set to slide.

Revamp Of Small Business Funding Scheme Set For Yet Another Delay By Congress

SBIR update: House and Senate can't agree in time on bill prized by cash-hungry biotech industry. End-of-January deadline is set to slide.

Industry Roundtable: Neurotech Execs Discuss Innovation, Challenges, Next Steps (part 2 of 4)

In part II of a series, panelists discuss venture capital, NIH grants, SBIR and foundation funding, as ways to support discovery.

Related Content

Topics

UsernamePublicRestriction

Register

PS067690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel